title: Lymphoma studies by the Australasian Leukaemia and Lymphoma Group.
abstract: The Australasian Leukaemia and Lymphoma Group (ALLG) can trace its origins to 1973. It now encompasses virtually all the major hospitals in Australia and New Zealand that treat leukaemias and lymphomas. Over the years the Group as a whole, and members individually, have participated in many clinical treatment trials for aggressive lymphomas. Initially trials were conceived and carried out locally, but in recent years, in addition to continuing its own studies, the Group has been a major contributor to international trials including two that have been particularly influential, known as MInT and CORAL. The MInT study confirmed the value of adding rituximab to standard chemotherapy for aggressive lymphomas; CORAL helped define optimum methods of autografting for relapse. The ALLG has contributed and continues to contribute to the improving outcome for patients with aggressive lymphomas.
authors: Royal Hobart Hospital, University of Tasmania, GPO Box 252C, Hobart, Tasmania 7001, Australia. Electronic address: r.m.lowenthal@utas.edu.au.
authors: R M
authors: RM
authors: Lowenthal
authors: J M
authors: JM
authors: Stone
mesh_terms: D001315:Australia; D002986:Clinical Trials as Topic; D007938:Leukemia / Q000175:diagnosis / Q000628:therapy*; D008223:Lymphoma / Q000175:diagnosis / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009520:New Zealand